A new lawsuit has been filed against a major pharmaceutical company, alleging severe injuries from the use of a widely prescribed diabetes medication. Lydia Adams, through her attorneys at Morgan & Morgan, filed the complaint in the United States District Court for the Northern District of Alabama on June 19, 2024, naming Novo Nordisk A/S and its affiliates as defendants.
The case centers around Adams' use of Ozempic, an injectable prescription medication used to control blood sugar in adults with type 2 diabetes. According to the complaint, Adams used Ozempic from September 2021 to March 2022 and subsequently developed gastroparesis—a condition that affects normal muscle movement in the stomach—resulting in severe and permanent personal injuries. The plaintiff alleges that Novo Nordisk failed to adequately warn users about the risk of gastroparesis associated with Ozempic, despite being aware of such risks from clinical trials and medical literature.
Gastroparesis can cause symptoms like nausea, vomiting (including vomiting undigested food), abdominal pain, bloating, severe dehydration, and weight loss. The lawsuit claims that Novo Nordisk downplayed these gastrointestinal side effects and did not provide sufficient warnings about the potential severity of these conditions. "Defendants have downplayed the severity of gastrointestinal events caused by their GLP-1RAs," states the complaint.
Adams seeks compensatory damages for her injuries, which include physical pain, mental anguish, diminished enjoyment of life, and ongoing medical expenses. She also requests punitive damages due to what she describes as willful negligence on the part of Novo Nordisk in failing to warn about known risks associated with Ozempic.
The legal team representing Lydia Adams includes attorneys from Morgan & Morgan. The case is presided over by Judge KSM under Case No. 2:24-cv-03012-KSM.